We are studying an investigational drug, Efruxifermin, to see if it will help in the treatment of liver inflammation and scarring (fibrosis) in adults diagnosed with Compensated Cirrhosis due to NASH (non-alcoholic steatohepatitis) and MASH (metabolic dysfunction-associated steatohepatitis).

We are studying an investigational drug, Efruxifermin, to see if it will help in the treatment of liver inflammation and scarring (fibrosis) in adults diagnosed with NASH (non-alcoholic steatohepatitis) and MASH (metabolic dysfunction-associated steatohepatitis).

This study aims to investigate the effectiveness and safety of retatrutide, a new diabetes medication) at doses of 4 mg, 9 mg, or 12 mg that will be taken as a weekly injection for about 1 year, compared to a placebo. A participant's change in HbA1c level will be primary outcome of interest. We are seeking participants with type 2 diabetes that has affected kidney function and are currently taking long-acting insulin with metformin and/or a SGLT2 inhibitor.

The purpose of this study is to compare diet (record of the foods you eat), gut microbiome (stool sample), and cells (blood sample) in adults with IgA Nephropathy (IgAN) and compare with adults with focal segmental glomerulosclerosis (FSGS) and adults with no history of medical problems. The information we learn by doing this study may help us understand how we might be able to target the microbiome to better understand the disease process and potentially help us develop new therapies in the future.

The study treatment, finerenone, is being developed to help people who have long lasting kidney disease, also known as chronic kidney disease (CKD). It works by blocking a certain hormone called aldosterone that causes injury and inflammation in the heart and kidney which is known to play a role in CKD. In this study, the researchers want to learn if finerenone works the same way in kidney transplant recipients. Some subjects will receive the study drug and some will receive a placebo.

Do you have multiple myeloma with MGRS-associated kidney disease? If so, you may be able to take part in a research study looking at the safety and effectiveness of a combination of medications for patients with multiple myeloma with MGRS-associated kidney disease.

We would like to learn about how people who apply for healthcare financial assistance experience the application process, including things that make the application process work well or that were challenging. At this time we are not able to offer interviews to people who applied to UNC or Duke, we are interested in hearing from people who applied to other programs (such as Atrium, Novant, Wake, Vidant, ECU, Cape Fear Health Net, Physicians Reach Out, or Project Access).

Help shape the future of lupus! Do you want to provide a game-changing contribution to lupus-centered research? Help us make clinical research more efficient and effective. If you have lupus, you can participate by providing samples we can study, such as blood, urine, saliva, and/or stool, to help doctors combat lupus head-on. Compensation provided.

The purpose of this study is to learn if a study medication called semaglutide (known as Ozempic) improves blood sugar control in people treated with dialysis.

In this study, we will learn more about the safety and effectiveness of a study treatment that is injected into one of the kidneys of patients with Chronic Kidney Disease and Type 2 Diabetes.